Hepatic Manifestations and Effect of Long COVID-19 on Patients With Chronic Liver Disease
1 other identifier
observational
65
1 country
1
Brief Summary
To measure the frequency of persistent liver dysfunction (raised liver enzymes, serum albumin, prothrombin time, etc) in recovered COVID -19 patients. To compare the hepatic manifestations in post COVID -19 patients with and without liver disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 19, 2021
CompletedFirst Posted
Study publicly available on registry
August 10, 2021
CompletedStudy Start
First participant enrolled
August 19, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2023
CompletedFebruary 6, 2023
February 1, 2023
1.6 years
March 19, 2021
February 3, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
to evaluate the long term effect of COVID 19 on the liver
to evaluate the changes in liver function (bilirubin ,liver enzymes , albumin , prothrombin time and INR in patients post COVID\_19
1 month
Secondary Outcomes (1)
: Effect of COVID 19 on diseased liver
1 month
Study Arms (2)
control group non cirrhotic
compare liver function 1m after COVID-19 and that at beginning of infection
cirrhotic patients
compare liver function 1m after COVID-19 and that at beginning of infection
Interventions
analytic
Eligibility Criteria
Patients older than 18 years old, 1 month post COVID 19 infection.
You may qualify if:
- Patients previously diagnosed by COVID 19 eg : PCR and / or HRCT chest, lab of more than 1 month duration.
You may not qualify if:
- Patients less than 18 y.
- Patients with acute COVID 19.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Medicine
Asyut, Egypt
Related Publications (3)
Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci. 2020 Mar 15;16(10):1686-1697. doi: 10.7150/ijbs.45472. eCollection 2020.
PMID: 32226286BACKGROUNDFung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558-570. doi: 10.1080/22221751.2020.1736644. eCollection 2020.
PMID: 32172672BACKGROUNDSultan S, Lim JK, Altayar O, Davitkov P, Feuerstein JD, Siddique SM, Falck-Ytter Y, El-Serag HB; AGA Institute. Electronic address: ewilson@gastro.org. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology. 2020 Aug;159(2):739-758.e4. doi: 10.1053/j.gastro.2020.03.072. Epub 2020 Apr 1. No abstract available.
PMID: 32247018BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Khaled Abu Bakr
Assiut University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- clinical professor : Mohammed El Taher Abdel Rahman .
Study Record Dates
First Submitted
March 19, 2021
First Posted
August 10, 2021
Study Start
August 19, 2021
Primary Completion
April 1, 2023
Study Completion
April 30, 2023
Last Updated
February 6, 2023
Record last verified: 2023-02